Sensus Healthcare Inc. (SRTS) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for SRTS, including 2 earnings updates, 2 SEC filings and 1 press release or news item. The most recent was published Nov 13, 2026.
SRTS rankings
Financial highlights
Full financials- Revenue, TTM
- $16.62M
- Revenue growth
- -53.3%
- Net income, TTM
- -$16.04M
- Net margin
- -96.5%
- Free cash flow, TTM
- -$11.53M
- Cash
- $12.92M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks16+100%
2026-05-242026-11-15
Mix1090d
- Insider5(50%)
- Earnings2(20%)
- SEC Filings2(20%)
- Other1(10%)
Activity · 52 weeks4834 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by Sensus Healthcare Inc.10-Q - Sensus Healthcare, Inc. (0001494891) (Filer)
- SECSensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
- PRSensus Healthcare Reports Third Quarter 2026 Financial Results and Business HighlightsCommercial Momentum Builds with Broader Physician Engagement and Customer Adoption New Dermatology Group Relationships Support Customer Expansion and Diversification Strategy Increasing Patient Awareness and International Commercial Activities Create Additional Growth Opportunities Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended September 30, 2026. Highlights included: Revenues of $6.0 million compared with $6.9 million in the third quarter of 2025, reflecting a pr
- PRSensus Healthcare Announces Sale of 1,000th SRT System, Marking Significant Commercial MilestoneAchievement reflects growing adoption of non-invasive superficial radiotherapy for the treatment of non-melanoma skin cancer New reimbursement environment supports opportunities for broader physician adoption and expanded patient access Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the sale of its 1,000th superficial radiotherapy (SRT) system, representing an important achievement in the Company's commercial development. This sale underscores Sensus' continued efforts to expand access to SRT as a non-invasive treatment option for non-m
- PRSensus Healthcare to Report Third Quarter 2026 Financial Results and Hold Business Update Conference Call on November 12, 2026Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the third quarter of 2026 on Thursday, November 12, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to p
- INSIDERDirector Sachetta Eric bought $225,616 worth of shares (64,841 units at $3.48), increasing direct ownership by 28% to 294,784 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERDirector Sachetta Eric bought $66,682 worth of shares (20,633 units at $3.23), increasing direct ownership by 10% to 229,943 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERDirector Sachetta Eric bought $112,904 worth of shares (34,697 units at $3.25), increasing direct ownership by 20% to 209,310 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Sardano Joseph C bought $60,486 worth of shares (20,000 units at $3.02), increasing direct ownership by 2% to 1,220,293 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERDirector Sachetta Eric bought $97,850 worth of shares (31,000 units at $3.16), increasing direct ownership by 22% to 174,613 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- SECSEC Form 10-Q filed by Sensus Healthcare Inc.10-Q - Sensus Healthcare, Inc. (0001494891) (Filer)
- PRSensus Healthcare Reports Second Quarter 2026 Financial Results and Business HighlightsCommercial Momentum Builds Following CPT Code Implementation Revenue Recognition on Eight Purchased Units Shifted to Q3 Due to Financing Approval Timing CMS Proposed 26% Increase in Hospital-Based Delivery Code, Further Strengthening the Reimbursement Outlook for SRT Customer Adoption, Pipeline Development and Commercial Expansion Advanced Across U.S. and International Markets Company Remains Focused on Delivering Strong Second Half Performance Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights
- SECSensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
- PRSensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 2026Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the second quarter of 2026 on Thursday, August 13, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pr
- SECSensus Healthcare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
- SECSensus Healthcare Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
- SECSEC Form 10-Q filed by Sensus Healthcare Inc.10-Q - Sensus Healthcare, Inc. (0001494891) (Filer)
- INSIDERDirector Sachetta Eric bought $5,002 worth of shares (1,500 units at $3.33), increasing direct ownership by 1% to 143,613 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- SECSensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
- PRSensus Healthcare Reports First Quarter 2026 Financial Results and Business HighlightsDedicated CPT Codes for Superficial Radiotherapy (SRT) Now Effective, Driving Increased Customer Activity, Customer Diversification and Improved Physician Economics Sales Pipeline and Financing Activity Strengthen Following Reimbursement Clarity Expansion of Installed Base and Recurring Revenue Growth Driving Advancement Towards Profitability Exited the Quarter with $18.3 Million in Cash and No Debt Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended March 31, 2026. Hig
- SECSEC Form DEF 14A filed by Sensus Healthcare Inc.DEF 14A - Sensus Healthcare, Inc. (0001494891) (Filer)
- PRSensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the first quarter of 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre
- INSIDERAmendment: SEC Form 4 filed by Sachetta Eric4/A - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Rampolla Javier4/A - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Martinez Magdalena3/A - Sensus Healthcare, Inc. (0001494891) (Issuer)
SRTS FAQ
11 questionsWhat does Sensus Healthcare Inc. do?
Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides...What is the latest news on SRTS?
In the last 30 days Quantisnow tracked 5 wire items for SRTS: 2 earnings updates, 2 SEC filings and 1 press release or news item. The most recent was published on November 13, 2026.What is SRTS revenue?
Sensus Healthcare Inc. (SRTS) reported $16.62M of revenue for the twelve months ended Sep 30, 2026. That is down 53.3% from the year before. Revenue for fiscal 2025 was $27.48M.Is SRTS profitable?
No. Sensus Healthcare Inc. reported a net loss of $16.04M for the twelve months ended Sep 30, 2026.How much cash and debt does SRTS have?
Sensus Healthcare Inc. reported $12.92M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does SRTS stock trade?
Sensus Healthcare Inc. (SRTS) is listed on NASDAQ.What sector and industry is SRTS in?
Sensus Healthcare Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Sensus Healthcare Inc. go public?
Sensus Healthcare Inc. (SRTS) completed its IPO in 2016.What are analysts saying about SRTS?
Sensus Healthcare Inc. has had 8 recent analyst actions on file. The most recent action was from Alliance Global Partners: Buy with a $7.50 price target on 2026-03-06. Recent price targets range from $7.00 to $18.00.What companies are similar to SRTS?
Notable peers in the same industry include ARAY (Accuray Incorporated). Compare SRTS side-by-side with any of them on Quantisnow.How can I track SRTS on Quantisnow?
Quantisnow aggregates Sensus Healthcare Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SRTS to receive live email and push alerts on every new disclosure.